Tocilizumab

Red

Brand Name(s):RoActemra

Indication:COVID-19 pneumonia

Rheumatoid arthritis in adults & Systemic juvenile idiopathic arthritis in children

Rationale:1,2,3,4,5,6

Considered:Jan-09

Review Date:Jan-26

Comments:
Emergent (non-published) data from the immune modulation arm of the REMAP-CAP trial indicate positive benefits with the use of tocilizumab in patients admitted to an intensive care unit (ICU) with severe pneumonia associated with Covid-19.